Sign In
Buy AKRO
$54.65
+0 (+0%)
At Close: Mar 06, 2026
Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback? | The Motley Fool
11:02am, Wednesday, 01'st Jul 2020
An approval pathway for OCA in treating NASH still exists. But it appears to be a steeper path.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Catasys (CATS
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ObsEva SA
Akero Therapeutics (NASDAQ:AKRO) Price Target Increased to $41.00 by Analysts at JPMorgan Chase & Co.
09:54am, Wednesday, 01'st Jul 2020
Akero Therapeutics (NASDAQ:AKRO) had its price objective hoisted by equities researchers at JPMorgan Chase & Co. from $28.00 to $41.00 in a research report issued on Wednesday, The Fly reports. The br
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Intercept Pharmaceuticals, Inc.
GENFIT : Résultats de l'assemblée générale ordinaire du 30 juin 2020 | Zone bourse
08:05pm, Tuesday, 30'th Jun 2020
Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED study of efruxifermin (EFX), formerly known as AKR
Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why.
03:53pm, Tuesday, 30'th Jun 2020
Uncertainty over its NASH drug weighs on the stock.
ENDRA Life Sciences Submits 510(k) Application to the US FDA for TAEUS(R) Liver Device | | IT Business Net
03:11pm, Tuesday, 30'th Jun 2020
Regulatory submission marks another major step toward commercialization of TAEUS liver device in 2020 ANN ARBOR, MI / ACCESSWIRE / June 30, 2020 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:
Grassley Says Talks On Drug Pricing Bill Are Broken, Pledges To Push GOP Bill Through Senate
01:03pm, Tuesday, 30'th Jun 2020
The Iowa senator’s comments could signal that there is little chance for a bill this year that would rein in drug prices, a policy that voters have expressed keen interest in.
Intercept CEO lays into FDA after NASH drug rejection -
09:48am, Tuesday, 30'th Jun 2020
Intercept Pharmaceuticals has accused the FDA of moving the goalposts during its review of a potential blockbuster drug for the fatty liver disease known as NASH following a rejection.
Legend Biotech (NASDAQ:PLRX) Now Covered by Analysts at Piper Sandler
04:32am, Tuesday, 30'th Jun 2020
Piper Sandler assumed coverage on shares of Legend Biotech (NASDAQ:PLRX) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The brokerage issued an overweight rati
LOS ANGELES--(BUSINESS WIRE)--$ICPT #fraud--Glancy Prongay & Murray LLP ("GPM"), a leading national shareholder rights law firm, today announced that it has commenced an investigation on
Dow Surges 2.3% as Boeing Begins Testing the 737 Max
12:00am, Tuesday, 30'th Jun 2020
Stocks Analysis by Zacks Investment Research covering: Boeing Co, Ciena Corp, Lennar Corporation, Verizon Communications Inc. Read Zacks Investment Research's latest article on Investing.com
EDISON, NJ / ACCESSWIRE / June 29, 2020 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease ari
